Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
93.47 -4.16 -4.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 34 in the most recent period (2026/Q3).
  • Total institutional ownership fell 3.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
106.95% -3.41pp
Institutions
365 +34
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund71.02%
Hedge Fund20.48%
VC/PE Fund10.81%
Individual/Insider5.29%
Public Company3.45%
Private Company0.50%
Government Pension Fund0.29%
Insurance Company0.25%
Endowment Fund0.13%

Top holders as of 2026-09-30

FMR 14.21% · 13.50M sh
BlackRock 7.14% · 6.78M sh
Paradigm Biocapital Advisors LP 4.69% · 4.46M sh
Perceptive Advisors LLC 4.55% · 4.32M sh
RTW Investments, LP 4.48% · 4.25M sh
Vanguard Portfolio Management, LLC 4.28% · 4.06M sh
Vanguard Capital Management, LLC 3.95% · 3.75M sh
Peter Deutsch 3.74% · 3.55M sh
State Street Global Advisors 3.72% · 3.53M sh
Capital Research 3.15% · 2.99M sh
VR Management, LLC 3.39% · 2.99M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 13 buys · 37 sells

NameRoleStake
Cameron Turtle Chief Executive Officer 0.57%
Peter Harwin Former Independent Director 0.43%
Tomas Kiselak Independent Director 0.43%
Michael Henderson Independent Director 0.07%
Scott Burrows Chief Financial Officer 0.05%
Jeffrey Albers Independent Chairperson 0.01%
Heidy King-Jones Chief Legal Officer 0.00%
Mark McKenna Director --
Laurie Stelzer Independent Director --
Fairmount Funds Management LLC -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-30 Cameron Turtle Chief Executive Officer Automatic Disposition -15,000 $89.14–93.91
2026-09-30 Heidy King-Jones Chief Legal Officer Derivative Exercise and Sale -28,933 $14.50–93.46
2026-09-30 Scott Burrows Chief Financial Officer Derivative Exercise and Sale -25,000 $14.50–93.57
2026-09-29 Scott Burrows Chief Financial Officer Intent to Sell (Form 144) -17,500 $89.89
2026-09-01 Heidy King-Jones Chief Legal Officer Derivative Exercise and Sale -28,399 $14.50–90.00
2026-09-01 Scott Burrows Chief Financial Officer Open Market Disposition -18,232 $89.35
2026-08-31 Cameron Turtle Chief Executive Officer Automatic Disposition -15,000 $86.36–89.07
2026-08-31 Heidy King-Jones Chief Legal Officer Intent to Sell (Form 144) -46,665 $89.33
2026-08-31 Scott Burrows Chief Financial Officer Derivative Exercise and Sale -7,500 $14.50–89.04
2026-08-06 Jeffrey Albers Independent Chairperson Automatic Disposition -18,000 $104.38–104.68
2026-08-06 Jeffrey Albers Independent Chairperson Derivative Exercise and Sale -5,000 $10.39–104.47
2026-08-02 Cameron Turtle Chief Executive Officer Automatic Disposition -15,000 $93.97–97.46
2026-08-02 Scott Burrows Chief Financial Officer Derivative Exercise and Sale -7,500 $14.50–97.10
2026-06-30 Cameron Turtle Chief Executive Officer Automatic Disposition -15,000 $87.44–88.91
2026-06-30 Scott Burrows Chief Financial Officer Derivative Exercise and Sale -7,500 $14.50–88.37
2026-06-30 Sheldon Sloan Chief Medical Officer Derivative Exercise and Sale -8,334 $27.46–88.34
2026-06-24 Scott Burrows Chief Financial Officer Derivative Exercise and Sale -15,000 $14.50–87.14
2026-06-22 Fairmount Funds Management LLC -- Private Disposition -4,018,101 $85.31
2026-06-22 Fairmount Funds Management LLC -- Derivative Exercise and Sale -666,680 $85.31
2026-06-21 Michael Henderson Independent Director Automatic Disposition -20,000 $100.00

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Spyre Therapeutics discussion 0 comments

Add a comment